[4-(3,5-Dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone → HCID 71253082, Verbindung

HRID 2411388Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2411388
[CH2:1]([C@@H:3]1[CH2:7][CH2:6][S:5](=[O:9])(=[O:8])[NH:4]1)[CH3:2].[CH3:10][C:11]1[C:12]([N:18]2[CH2:23][CH2:22][N:21]([C:24]([C:26]3[CH:31]=[CH:30][C:29](I)=[CH:28][CH:27]=3)=[O:25])[CH2:20][CH2:19]2)=[N:13][CH:14]=[C:15]([CH3:17])[CH:16]=1>>[CH3:10][C:11]1[C:12]([N:18]2[CH2:19][CH2:20][N:21]([C:24]([C:26]3[CH:31]=[CH:30][C:29]([N:4]4[C@H:3]([CH2:1][CH3:2])[CH2:7][CH2:6][S:5]4(=[O:9])=[O:8])=[CH:28][CH:27]=3)=[O:25])[CH2:22][CH2:23]2)=[N:13][CH:14]=[C:15]([CH3:17])[CH:16]=1

Komponenten

3

Edukt 2

HCID 58484535[4-(3,5-Dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanoneHCID 86676750HCID 86676750, Verbindung

Produkt 1

HCID 71253082HCID 71253082, VerbindungAusbeute 12,9 %

Versuchsvorschrift

Using (R)-3-ethylisothiazolidine 1,1-dioxide (150 mg) described in Preparation Example 3 and [4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl](4-iodophenyl)methanone (421 mg) described in Preparation Example 113 and by the reaction and treatment in the same manner as in Example 1, the title compound (57 mg) was obtained.

Aufarbeitung

  1. customdescribed in Preparation Example 113 and by the reaction and treatment in the same manner as in Example 1

Quellen und Nachweise

ORD-Eintrag
ord-bfbd4945fcde464685b19661fcd24763
Quelldatensatz
uspto-grants-2014_08
Patentnummer
US08816079B2

Notizen zur Reaktion

Wird geladen…